Monte Rosa Therapeutics Management
Management criteria checks 4/4
Monte Rosa Therapeutics' CEO is Markus Warmuth, appointed in Jan 2020, has a tenure of 6.25 years. total yearly compensation is $2.44M, comprised of 25.3% salary and 74.7% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $8.62M. The average tenure of the management team and the board of directors is 2.3 years and 5.5 years respectively.
Key information
Markus Warmuth
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 25.25% |
| CEO tenure | 6.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today
Apr 21
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%
Feb 14Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
Jan 08Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Dec 03Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Held Back By Insufficient Growth Even After Shares Climb 58%
Oct 18Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth
Jul 18Revenues Working Against Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Share Price Following 26% Dive
May 24Results: Monte Rosa Therapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit
May 10Monte Rosa Therapeutics: Exercise Extreme Caution
Mar 24We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Feb 25Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
Feb 17Monte Rosa Therapeutics: A First Assessment
Dec 04News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts
Nov 12Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Oct 28We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Sep 23Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$39m |
| Sep 30 2025 | n/a | n/a | US$21m |
| Jun 30 2025 | n/a | n/a | US$24m |
| Mar 31 2025 | n/a | n/a | US$6m |
| Dec 31 2024 | US$2m | US$616k | -US$73m |
| Sep 30 2024 | n/a | n/a | -US$119m |
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$4m | US$616k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$133m |
| Jun 30 2023 | n/a | n/a | -US$125m |
| Mar 31 2023 | n/a | n/a | -US$117m |
| Dec 31 2022 | US$4m | US$582k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$94m |
| Mar 31 2022 | n/a | n/a | -US$86m |
| Dec 31 2021 | US$5m | US$525k | -US$74m |
| Sep 30 2021 | n/a | n/a | -US$70m |
| Jun 30 2021 | n/a | n/a | -US$57m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$2m | US$465k | -US$36m |
Compensation vs Market: Markus's total compensation ($USD2.44M) is below average for companies of similar size in the US market ($USD5.34M).
Compensation vs Earnings: Markus's compensation has been consistent with company performance over the past year.
CEO
Markus Warmuth (53 yo)
Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$2.44m | 0.53% $ 8.6m | |
| Chief Business & Legal Officer | 4.1yrs | US$1.29m | 0.0073% $ 117.8k | |
| Chief Medical Officer | 4.8yrs | US$1.26m | 0.0098% $ 158.0k | |
| Corporate Controller & Principal Accounting Officer | no data | no data | 0.023% $ 363.3k | |
| Chief Operating Officer | 5.1yrs | no data | 0.0061% $ 98.3k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Chief Data & Information Officer | 2.3yrs | no data | no data | |
| Chief Scientific Officer | 1.9yrs | no data | 0.0073% $ 117.8k | |
| Chief Investor Relations and Strategy Officer | 2.2yrs | no data | no data |
Experienced Management: GLUE's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$2.44m | 0.53% $ 8.6m | |
| Independent Director | 5.3yrs | US$124.02k | 0% $ 0 | |
| Independent Chairman of the Board | 5.6yrs | US$164.83k | 0% $ 0 | |
| Independent Director | 5.6yrs | no data | no data | |
| Independent Director | 2.8yrs | US$112.50k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$111.44k | 0% $ 0 | |
| Scientific Advisor & Member of Scientific Advisory Board | 1.9yrs | US$1.42m | no data | |
| Independent Director | 5.8yrs | US$123.39k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$281.36k | 0% $ 0 | |
| Independent Director | 6yrs | US$117.77k | 0% $ 0 |
Experienced Board: GLUE's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/24 06:34 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Monte Rosa Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Michael Schmidt | Guggenheim Securities, LLC |
| Dingding Shi | Jefferies LLC |